David A. Fiellin, MD | Professor of Medicine, Investigative Medicine and Public Health Yale University School of Medicine
Module Description: Describes the legislation and basic components of office-based treatment of opioid use disorder with buprenorphine. Buprenorphine is a partial agonist opioid that is approved for the treatment of heroin and prescription opioid use disorder. The module outlines how through appropriate patient assessment and resource matching, evidence suggests that many, but not all, opioid dependent patients can achieve good treatment outcomes through office-based treatment with buprenorphine.
Note: This online module is not designated for AMA PRA Category 1 Credit™.